US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)

22.50

+2.1910.78%

Volume:3.33K

Turnover:74.51K

Market Cap:2.53B

PE:-11.14

High:22.50

Open:22.00

Low:22.00

Close:20.31

52wk High:29.99

52wk Low:5.45

Shares:112.63M

Float Shares:112.63M

Volume Ratio:4.22

T/O Rate:0.00%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0190

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

BRIEF-Newamsterdam Pharma Highlights 2025 Achievements And Outlines 2026 Strategic Priorities

NewAmsterdam Pharma Company Nv - Ema Approval Decision for Obicetrapib Expected in H2 2026

THOMSON REUTERS

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

THOMSON REUTERS

NewAmsterdam Pharma Company Nv - Rubens Phase 3 Trial Expected to Enroll Approximately 300 Patients, With Topline Data Expected by Year End 2026

THOMSON REUTERS

BRIEF-Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NAMSW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NAMSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)","latestPrice":22.5,"timestamp":1770670800000,"preClose":20.31,"halted":0,"volume":3326,"delay":0,"changeRate":0.10782865583456433,"floatShares":112628458,"shares":112628458,"eps":-2.019,"marketStatus":"Closed","change":2.19,"latestTime":"02-09 16:00:00 EST","open":22,"high":22.5,"low":22,"amount":74508.23,"amplitude":0.024618,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.019,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770714000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":20.31,"volumeRatio":4.221884},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","floatShares":112628458,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":4.221884,"shares":112628458,"dividePrice":0,"high":22.5,"amplitude":0.024618,"preClose":20.31,"low":22,"week52Low":5.45,"pbRate":"--","week52High":29.99,"institutionHeld":0,"latestPrice":22.5,"eps":-2.019,"divideRate":0,"volume":3326,"delay":0,"ttmEps":-2.019,"open":22,"prevYearClose":23,"prevWeekClose":20.31,"prevMonthClose":19.45,"prevQuarterClose":23,"fiveDayClose":20,"twentyDayClose":23.95,"sixtyDayClose":28.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAMSW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAMSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAMSW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NAMSW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602379355","title":"BRIEF-Newamsterdam Pharma Highlights 2025 Achievements And Outlines 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602379355","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602379355?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:36","pubTimestamp":1767965765,"startTime":"0","endTime":"0","summary":"BRIEF-Newamsterdam Pharma Highlights 2025 Achievements And Outlines 2026 Strategic PrioritiesJan 9 (Reuters) - NewAmsterdam Pharma Company NV KH6.F:NEWAMSTERDAM PHARMA HIGHLIGHTS 2025 ACHIEVEMENTS AND","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA62DKLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMSW"],"gpt_icon":0},{"id":"2602890376","title":"NewAmsterdam Pharma Company Nv - Ema Approval Decision for Obicetrapib Expected in H2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602890376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602890376?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:00","pubTimestamp":1767963602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA62DKLJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAMSW"],"gpt_icon":0},{"id":"2602737571","title":"NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2602737571","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602737571?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:00","pubTimestamp":1767963602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA62DKLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAMSW"],"gpt_icon":0},{"id":"2602376806","title":"NewAmsterdam Pharma Company Nv - Rubens Phase 3 Trial Expected to Enroll Approximately 300 Patients, With Topline Data Expected by Year End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376806?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:00","pubTimestamp":1767963602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nTUA62DKLJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAMSW"],"gpt_icon":0},{"id":"2601300028","title":"BRIEF-Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601300028","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601300028?lang=en_us&edition=fundamental","pubTime":"2026-01-06 06:13","pubTimestamp":1767651224,"startTime":"0","endTime":"0","summary":"BRIEF-Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NewAmsterdam Pharma Company NV KH6.F:NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)Source text: ID:nGNX5ZbcksFurther company coverage: KH6.F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nTUA3YCF2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAMSW"],"gpt_icon":0},{"id":"2589817788","title":"NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589817788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589817788?lang=en_us&edition=fundamental","pubTime":"2025-12-06 05:01","pubTimestamp":1764968460,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nTUAB4VK7L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NAMSW"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}